Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
Authors
Keywords
-
Journal
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-06-23
DOI
10.1016/j.jfma.2022.05.015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
- (2020) Po‐Han Lin et al. CANCER SCIENCE
- Durable Responses to Afatinib as First Line Therapy for HER2-Mutated Metastatic Non-Small Cell Lung Cancer
- (2019) Ebaa Al-Obeidi et al. Clinical Lung Cancer
- Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer
- (2018) Kenji Tamura et al. CANCER SCIENCE
- Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway
- (2018) Shi Yehui et al. Cancer Biology & Medicine
- Recent Advances in the Neoadjuvant Treatment of Breast Cancer
- (2017) Gábor Rubovszky et al. Journal of Breast Cancer
- Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2017) Dejan Juric et al. Cancer Discovery
- Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
- (2016) Sven Wind et al. CLINICAL PHARMACOKINETICS
- JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
- (2016) Sizhi P. Gao et al. Science Signaling
- Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma
- (2016) Xiaochun Wang et al. Oncotarget
- Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
- (2016) Chun-Yu Liu et al. Oncotarget
- JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
- (2016) Sizhi P. Gao et al. Science Signaling
- Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer
- (2015) Y. Kuboki et al. ANNALS OF ONCOLOGY
- Prospective Trial of Breast MRI Versus 2D and 3D Ultrasound for Evaluation of Response to Neoadjuvant Chemotherapy
- (2015) Marie Catherine Lee et al. ANNALS OF SURGICAL ONCOLOGY
- BRCAness Predicts Resistance to Taxane-Containing Regimens in Triple Negative Breast Cancer During Neoadjuvant Chemotherapy
- (2015) Sadako Akashi-Tanaka et al. Clinical Breast Cancer
- A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours
- (2015) A. Suder et al. EUROPEAN JOURNAL OF CANCER
- Comparative accuracy of preoperative tumor size assessment on mammography, sonography, and MRI: Is the accuracy affected by breast density or cancer subtype?
- (2015) Rebecca Leddy et al. JOURNAL OF CLINICAL ULTRASOUND
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Triple negative breast cancer: looking for the missing link between biology and treatments
- (2015) Giuseppe Palma et al. Oncotarget
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
- (2014) Christina Therkildsen et al. ACTA ONCOLOGICA
- Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer
- (2014) C. Wang et al. ANNALS OF ONCOLOGY
- Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data
- (2014) Valentina Boeva et al. BIOINFORMATICS
- Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies
- (2014) Alfredo Berruti et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
- (2014) E. C. de Bruin et al. Cancer Discovery
- Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer
- (2013) Shirish M. Gadgeel et al. Clinical Lung Cancer
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
- (2013) D. A. Ferraro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
- (2012) Eleftherios P. Mamounas et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study
- (2011) V. Semiglazov et al. EJSO
- Regulation of mitosis and taxane response by Daxx and Rassf1
- (2011) S Giovinazzi et al. ONCOGENE
- Triple-Negative Breast Cancer: An Unmet Medical Need
- (2011) C. A. Hudis et al. ONCOLOGIST
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started